1,236 results on '"Koschmieder, Steffen"'
Search Results
2. Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis
3. Evaluation of chiral organosulfur compounds on their activity against the malaria parasite 'Plasmodium falciparum'
4. Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial
5. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
6. Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study
7. Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
8. Correction: Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis
9. Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis
10. Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
11. Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche
12. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
13. Essenzielle Thrombozythämie und Polycythaemia vera
14. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
15. Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms
16. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
17. Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms
18. Towards personalized medicine with iPS cell technology: a case report of advanced systemic mastocytosis with associated eosinophilia
19. Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry
20. Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
21. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
22. 61/w mit Blutungen und Thrombose bei Thrombozytose: Vorbereitung auf die Facharztprüfung: Fall 32
23. Mast cells as a therapeutic target in myeloproliferative neoplasms
24. CXCR4 and CD74 together enhance cell survival in response to macrophage migration-inhibitory factor in chronic lymphocytic leukemia
25. NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms
26. Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives
27. Breakthrough infections in MPN-COVID vaccinated patients
28. Second versus first wave of COVID-19 in patients with MPN
29. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
30. Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells
31. Telemedizin in der Hämatologie und Onkologie
32. Kindlin-3 loss curbs chronic myeloid leukemia in mice by mobilizing leukemic stem cells from protective bone marrow niches
33. Potential Technologies Review: A Hybrid Information Retrieval Framework to Accelerate Demand-Pull Innovation in Biomedical Engineering
34. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
35. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms
36. Ph-negative myeloproliferative Neoplasien
37. Autoreninnen und Autoren
38. Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms
39. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet
40. Is Treatment for Cytopenic Myelofibrosis Still an Unmet Clinical Need?
41. A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system
42. Inflammatory Responses of Astrocytes Are Independent from Lipocalin 2
43. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
44. Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm
45. Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study
46. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
47. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms
48. Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
49. Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alpha
50. The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.